GF
TRIL

Gabelli Funds’s Trillium Therapeutics Inc. TRIL Stock Holding History

Gabelli Funds’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,793,880
Closed -$31.5M – 1481
2021
Q3 		$31.5M Buy
1,793,880
+1,481,780
+475% +$17.3M 0.21% 131
2021
Q2 		$3.03M Hold
312,100
– – 0.02% 652
2021
Q1 		$3.35M Buy
312,100
+77,100
+33% +$954K 0.02% 612
2020
Q4 		$3.46M Buy
+235,000
New +$3.39M 0.02% 571

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Gabelli Funds's TRIL Position: Q4 2021 in Review

Gabelli Funds sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,793,880 shares — an estimated $31.5M sold.

Gabelli Funds first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $31.5M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Gabelli Funds reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Gabelli Funds sold 1,793,880 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $31.5M.
  • Gabelli Funds first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
  • Gabelli Funds's Trillium Therapeutics Inc. position peaked at $31.5M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Gabelli Funds's 13F filing for Q4 2021, filed 11 Feb 2022.